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Background: Depression is a prevalent neuropsychiatric disorder that affects an estimated 350 million people
worldwide. Currently available treatments for depression are lacking in both speed of onset and efficacy. Recent
pharmacological efforts have targeted the glutamatergic neurotransmitter system using the N-methyl-D-aspartate
(NMDA) receptor antagonist ketamine to produce rapid and robust antidepressant effects, however the widespread
clinical use of ketamine is limited due to side effects and abuse liability. More recently, work evaluating
metabotropic mGluR2/3 receptor antagonists has demonstrated many similarities with ketamine.
Methods: Male, Sprague–Dawley rats were exposed to a chronic unpredictable stress paradigm, which produces
decreased sucrose preference, a measure of anhedonia. Rats were then treated with vehicle or a single injection of
the mGluR2/3 antagonist LY341495 (3 mg/kg, i.p.) and tested at 24 hrs, 48 hrs or 10 days after a single treatment.
Results: We demonstrate that a single treatment with LY341495 produces a rapid (within 1–2 days) and long-lasting
(10 days) reversal of anhedonia caused by chronic unpredictable stress in rats. This model provides a rigorous test of
rapid-acting agents as typical antidepressants require several weeks of treatment to produce a response.
Conclusions: These data suggest that LY341495 has the ability to produce rapid and robust antidepressant effects
similar to ketamine. Together, the results highlight the potential for similar compounds to produce rapid and lasting
efficacy for the treatment of depression.
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Major Depressive Disorder (MDD) is a debilitating
neuropsychiatric disorder that affects nearly one fifth
of the US population [1], and according to the World
Health Organization (WHO), affects an estimated 350
million people worldwide, making it the leading cause
of disability. Currently available antidepressants target
monoaminergic neurotransmitter systems, however these
agents produce limited efficacy (~33% initial response
rate) and require several weeks to months of chronic
treatment. Development of novel agents that produce a
rapid and robust antidepressant response represents a
major unmet medical need for the treatment of MDD.* Correspondence: ronald.duman@yale.edu
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reproduction in any medium, provided the orThe discovery that the non-competitive N-methyl-D-as-
partate (NMDA) receptor antagonist ketamine produces
rapid antidepressant effects in humans (within 2 hours)
that last roughly one week after a single intravenous
administration has generated interest in targeting the
glutamatergic system for the treatment of MDD [2,3].
Much like studies in humans, preclinical studies have
demonstrated that ketamine also produces rapid anti-
depressant effects in rodent models of depression, such
as the chronic unpredictable stress (CUS)-anhedonia
paradigm, which can detect agents with rapid onset of
action [4]. In addition, evidence suggests that ketamine
has the unique ability to rapidly reverse losses of excitatory
spine synapses in the medial prefrontal cortex (mPFC)
within 24 hrs following exposure to three weeks of CUS
[4]. Furthermore, this reversal of the behavioral and
neuronal deficits produced by CUS requires signalingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and


































Figure 1 LY341495 produces a rapid antidepressant effect. (A) LY341495 produced a trend toward a reversal of stress-induced decreased
sucrose preference at 24 hrs post-LY341495 treatment (not significant). (B) LY341495 reversed the stress-induced decrease in sucrose preference
48 hrs after a single treatment, indicating a rapid antidepressant effect. *P < 0.01 compared to No Stress/Vehicle; †P < 0.01 compared to

























Figure 2 The antidepressant effect of a single injection of
LY341495 was sustained for 10 days. **P < 0.001 compared to No
Stress/Vehicle; ‡P < 0.001 compared to Stress/Vehicle group; Stress x
LY341495 interaction P < 0.01 (two-way ANOVA; LSD post-hoc tests).
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(mTORC1) pathway [4,5], which is a ubiquitously expressed
serine/threonine kinase pathway involved in regulation of
cell growth and protein translation.
Given the side effect profile and abuse potential of
ketamine, its clinical use is limited. Therefore, efforts have
focused on developing drugs that target the glutamatergic
system to produce ketamine-like rapid antidepressant
responses without the side effects or abuse liability.
Recently, research has focused on targeting subtypes of
metabotropic glutamate receptors (mGluRs). One of the
most widely studied is the mGluR Group II. Group II
mGluRs consist of mGluR2 and mGluR3 subtypes and are
seven transmembrane G-protein coupled receptors
that negatively regulate adenylyl cyclase and function
to decrease neurotransmitter release. The mGluR2 receptor
is located pre- and post-synaptically [6] but is thought to be
predominantly located at the pre-terminal portion of axons
[7] where it functions as an autoreceptor. While mGluR2
expression seems to be confined to neurons [8], mGluR3
receptors, which are also pre- and post-synaptic, are located
on neurons as well as glia [9]. Studies have demonstrated
that these receptors are localized in regions associated with
depression and emotional responses, such as the mPFC
and hippocampus [10]. Additionally, a number of studies
have demonstrated that antagonists of Group II mGluRs
produce robust antidepressant responses in acute rodent
models [11,12].
Recently, work by a number of labs has demonstrated
similarities between ketamine and mGluR2/3 antagonists.
Much like ketamine, mGluR2/3 antagonists produce rapid
and transient increases in glutamate release in the mPFC
[13,14]. Blockade of post-synaptic AMPA receptors blocks
the antidepressant effects of both ketamine and mGluR2/3
antagonists in rodent models [15,16]. Interestingly, much
like ketamine, the behavioral antidepressant effects of
mGluR2/3 antagonists require signaling through the
mTORC1 pathway [17,18]. The selective mGluR2/3 an-
tagonist LY341495 increases activity of mTORC1 and itstwo major downstream substrates, p70 S6 kinase and
4E-BP1 [17]. Furthermore, this increase in mTORC1
pathway signaling is associated with increases in critical
synaptic proteins PSD-95, GluR1 and synapsin I [17].
These data suggest that, much like ketamine, mGluR2/3
antagonism may have the ability to rapidly reverse the
behavioral deficits produced by CUS. To examine this
possibility we employed a CUS model that results in
decreased preference for a sweetened solution (1% sucrose).
Reduced sucrose preference is a measure of anhedonia,
a core symptom of depression, which requires several
weeks of chronic treatment with typical antidepressants
to reverse.
Methods
Adult male Sprague–Dawley rats (Charles River) weighing
~300 g at the beginning of the experiment were randomly
assigned to control or CUS groups and exposed to CUS. In
brief, rats were exposed to 2 stressors per day consisting of
overnight isolation, manipulations of light cycle (i.e. light
on overnight or 3 hr light off during the light cycle),
stroboscopic light overnight, overnight food and water
deprivation, overnight crowding, overnight cage tilt, over-
night wet bedding, 1 hr restraint, 10 min swim in cold
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a rotator. Control rats were handled daily. After 28 days
of stress, rats were assessed for sucrose preference. Rats
exposed to CUS showed the expected lack of preference
for 1% sucrose compared to non-stressed control rats
(78% preference for control vs. 48% preference for CUS
P < 0.05, t-test). Control and CUS groups were then
divided and counterbalanced for vehicle and drug treatment
groups and given a single intraperitoneal (i.p.) injection
of vehicle (saline) or 3 mg/kg of the selective mGluR2/3
antagonist LY341495 (Tocris BioScience). Rats were then
tested 24 hrs, 48 hrs, and 10 days after drug administration.
All experiments were conducted in accordance with the
NIH guidelines for the care and use of laboratory animals
and were approved by the Yale University Institutional
Animal Care and Use Committee (IACUC).
Results and discussion
Results demonstrate a trend toward reversal of the de-
creased sucrose preference resulting from CUS exposure at
24 hrs and a significant reversal at 48 hrs post LY341495
treatment (Figure 1). These data suggest that LY341495
produces a rapid reversal of CUS-induced anhedonia
within days after a single treatment, an antidepressant effect
that requires weeks of administration of typical antide-
pressants. This rapid effect of LY341495 is similar to that
observed following ketamine treatment as previous studies
have shown a reversal of the deficit in sucrose preference
within 24 hrs of ketamine treatment [4]. While we failed
to find statistical significance at the 24 hr test following
LY341495 treatment, this is likely due to the high variability
within groups. No significant effects of LY341495 on water
consumed or total fluid consumed were observed.
To assess whether LY341495 also produces long-lasting
antidepressant effects, the same rats were tested 10 days
after the initial injection of LY341495 with continued
exposure to CUS. Much like the data observed at 48 hours
post-injection, CUS-induced anhedonia was still signifi-
cantly blocked in rats that were administered LY341495
10 days earlier, demonstrating a long-lasting antidepressant
response following a single treatment (Figure 2).
The CUS model is an ideal rodent model for testing
putative rapid-acting antidepressants. Given that typical
antidepressants, such as imipramine, fluoxetine, and other
monoamine reuptake inhibitors, require several weeks of
chronic treatment [19], the CUS model allows for detection
of rapid-acting agents. For example, typical antidepressants
fail to reverse the effects of chronic stress following 1 week
of treatment [19]. Taken together, the data presented here
demonstrate that mGluR2/3 antagonists are capable of
producing rapid and long-lasting antidepressant effects.
Given that LY341495 produces a very similar biochemical
signature to ketamine (i.e. increases in mTORC1 signaling
and synaptic protein content), which is required for theantidepressant effects of mGluR2/3 blockade, drugs tar-
geting mGluR2/3 receptors hold promise as future antide-
pressants. It is interesting to note that antidepressant
responses to LY341495 are observed long after the
half-life of the drug (~45 min following i.p. injection)
[20], suggesting that it is likely that mGluR2/3 blockade
produces morphological and functional changes in mPFC
neurons reminiscent of those produced by ketamine. Future
experiments measuring spine density and excitatory post-
synaptic potentials will be necessary to determine if this
is the case. Additionally, it will be interesting to see if
LY341495 reverses HPA axis dysregulation observed
following chronic stress. Given that the goal of drug dis-
covery for MDD is to identify agents that lack ketamine’s
side-effect and abuse potential, future studies will also need
to address these issues with putative mGluR2/3 antidepres-
sants. Future experiments with novel pharmacological tools
will be necessary to identify the specific roles of mGluR2
and mGluR3 receptors in mediating these rapid responses.
Conclusion
The mGluR2/3 antagonist LY341495 produces rapid
and long-lasting antidepressant effects in the rodent
CUS model. These data suggest that drugs targeting
mGluR2/3 receptors may hold promise for rapid and
lasting treatment of patients suffering from MDD.
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